References
99
33. Hu B et al (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding
to MDM2 and MDMX. Can Res 67(18):8810–8817
34. Baek S et al (2012) Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc
134(1):103–106
35. Chen L et al (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of
MDM2 expression. Mol Med 5(1):21–34
36. Ventura A et al (2007) Restoration of p53 function leads to tumour regression in vivo. Nature
445(7128):661–665
37. Wang W et al (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering
phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23(6):2171–2181
38. Brooks H et al (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv
Rev 57(4):559–577
39. Zhang X et al (2013) Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition
in cancer cells. Cell Reports 5(2):445–457
40. Wahl AF et al (1996) Loss of normal p53 function confers sensitization to taxol by increasing
G2/M arrest and apoptosis. Nat Med 2(1):72–79
41. Ryan KM et al (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin
Cell Biol 13(3):332–337
42. Hsieh J-K et al (1999) RB regulates the stability and the apoptotic function of p53 via MDM2.
Mol Cell 3(2):181–193
43. Huang B et al (2009) Pharmacologic p53 activation blocks cell cycle progression but fails to
induce senescence in epithelial cancer cells. Mol Cancer Res 7(9):1497–1509
44. Pishas KI et al (2011) Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res
17(3):494–504
45. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21(3):307–315
46. Paek Andrew L et al (2016) Cell-to-cell variation in p53 dynamics leads to fractional killing.
Cell 165(3):631–642
47. Kelly PN et al (2007) Tumor growth need not be driven by rare cancer stem cells. Science
317(5836):337–337
48. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med, 313–319
49. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence
and unresolved questions. Nat Rev Cancer 8(10):755–768
50. Takebe N et al (2011) Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog
pathways. Nat Rev Clin Oncol 8(2):97–106
51. Vermeulen L et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the
microenvironment. Nat Cell Biol 12(5):468–476
52. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland
Biol Neoplasia 14(1):3–9
53. Liu C et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med 17(2):211–215
54. Holohan C et al (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer
13(10):714–726
55. Watt FM et al (2000) Out of eden: stem cells and their niches. Science 287(5457):1427–1430
56. Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Can Res
66(9):4553–4557
99
33. Hu B et al (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding
to MDM2 and MDMX. Can Res 67(18):8810–8817
34. Baek S et al (2012) Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc
134(1):103–106
35. Chen L et al (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of
MDM2 expression. Mol Med 5(1):21–34
36. Ventura A et al (2007) Restoration of p53 function leads to tumour regression in vivo. Nature
445(7128):661–665
37. Wang W et al (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering
phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23(6):2171–2181
38. Brooks H et al (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv
Rev 57(4):559–577
39. Zhang X et al (2013) Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition
in cancer cells. Cell Reports 5(2):445–457
40. Wahl AF et al (1996) Loss of normal p53 function confers sensitization to taxol by increasing
G2/M arrest and apoptosis. Nat Med 2(1):72–79
41. Ryan KM et al (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin
Cell Biol 13(3):332–337
42. Hsieh J-K et al (1999) RB regulates the stability and the apoptotic function of p53 via MDM2.
Mol Cell 3(2):181–193
43. Huang B et al (2009) Pharmacologic p53 activation blocks cell cycle progression but fails to
induce senescence in epithelial cancer cells. Mol Cancer Res 7(9):1497–1509
44. Pishas KI et al (2011) Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res
17(3):494–504
45. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21(3):307–315
46. Paek Andrew L et al (2016) Cell-to-cell variation in p53 dynamics leads to fractional killing.
Cell 165(3):631–642
47. Kelly PN et al (2007) Tumor growth need not be driven by rare cancer stem cells. Science
317(5836):337–337
48. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med, 313–319
49. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence
and unresolved questions. Nat Rev Cancer 8(10):755–768
50. Takebe N et al (2011) Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog
pathways. Nat Rev Clin Oncol 8(2):97–106
51. Vermeulen L et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the
microenvironment. Nat Cell Biol 12(5):468–476
52. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland
Biol Neoplasia 14(1):3–9
53. Liu C et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med 17(2):211–215
54. Holohan C et al (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer
13(10):714–726
55. Watt FM et al (2000) Out of eden: stem cells and their niches. Science 287(5457):1427–1430
56. Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Can Res
66(9):4553–4557